Neuroone Medical Technologies CORP (NMTC) — SEC Filings

Overview

Neuroone Medical Technologies CORP (NMTC) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 4 filed on Apr 7, 2026: On April 3, 2026, Jeffrey S. Mathiesen reported a change in beneficial ownership of securities for NeuroOne Medical Technologies Corp. The filing details transactions related to his holdings, but specific details on the nature of the transaction, number of shares, or dollar amounts are not provided

Sentiment Summary

Across 38 filings, the sentiment breakdown is: 2 bearish, 34 neutral, 2 mixed. The dominant filing sentiment for Neuroone Medical Technologies CORP is neutral.

Filing Type Overview

Neuroone Medical Technologies CORP (NMTC) has filed 2 4, 19 8-K, 2 10-K, 6 10-Q, 1 8-K/A, 2 DEFA14A, 2 DEF 14A, 2 SC 13G/A, 2 SC 13G with the SEC between Jan 2024 to Apr 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (38)

• NeuroOne Medical Technologies: Insider Ownership Update — 4 · Apr 7, 2026 Risk: low
  On April 3, 2026, Jeffrey S. Mathiesen reported a change in beneficial ownership of securities for NeuroOne Medical Technologies Corp. The filing details transa
• NEUROONE MEDICAL TECHNOLOGIES Corp Files Form 4 — 4 · Apr 7, 2026 Risk: low
  On April 7, 2026, NEUROONE MEDICAL TECHNOLOGIES Corp filed a Form 4, reporting changes in beneficial ownership of securities. The report covers transactions tha
• 8-K Filing — 8-K · Dec 22, 2025
• NeuroOne Eyes Billion-Dollar Markets with New Neurological Devices — 10-K · Dec 17, 2025 Risk: high
  NeuroOne Medical Technologies Corp (NMTC) is a medical technology company focused on diagnostic, ablation, and deep brain stimulation technologies for neurologi
• 8-K Filing — 8-K · Nov 5, 2025
• NeuroOne Medical Technologies Corp. Files 8-K — 8-K · Oct 6, 2025 Risk: low
  NeuroOne Medical Technologies Corp. filed an 8-K on October 6, 2025, reporting on its results of operations, financial condition, and other events. The filing a
• NeuroOne Medical Technologies Files 8-K — 8-K · Aug 18, 2025 Risk: low
  On August 18, 2025, NeuroOne Medical Technologies Corporation filed an 8-K report. The filing indicates a change in the company's principal executive offices to
• NeuroOne Medical Files 8-K — 8-K · Aug 15, 2025 Risk: low
  NeuroOne Medical Technologies Corp. filed an 8-K on August 15, 2025, reporting on other events and financial statements/exhibits. The filing does not contain sp
• NeuroOne's Revenue Soars 99.8%, Narrows Loss on Strong Product Sales — 10-Q · Aug 14, 2025 Risk: medium
  NEUROONE MEDICAL TECHNOLOGIES Corp reported a significant increase in product revenue for the nine months ended June 30, 2025, reaching $6,356,767, a 99.8% incr
• NeuroOne Medical Technologies Files Q1 2025 10-Q — 10-Q · May 13, 2025 Risk: low
  NeuroOne Medical Technologies Corp. filed its 10-Q for the quarterly period ended March 31, 2025. The company, incorporated in Delaware with its principal execu
• NeuroOne Medical Technologies Faces Delisting Concerns — 8-K · May 9, 2025 Risk: high
  NeuroOne Medical Technologies Corporation filed an 8-K on May 9, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule or standar
• NeuroOne Medical Technologies Corp. Files 8-K — 8-K · Apr 7, 2025 Risk: medium
  NeuroOne Medical Technologies Corp. entered into a material definitive agreement on April 4, 2025. The company, incorporated in Delaware with its principal exec
• NeuroOne Medical Technologies Files 8-K Amendment — 8-K/A · Feb 20, 2025 Risk: low
  NeuroOne Medical Technologies Corporation filed an amendment (8-K/A) on February 20, 2025, to its Form 8-K originally dated February 14, 2025. This amendment pe
• NeuroOne Medical Votes on Shareholder Matters — 8-K · Feb 14, 2025 Risk: low
  NeuroOne Medical Technologies Corporation filed an 8-K on February 14, 2025, to report on matters submitted to a vote of its security holders. The filing detail
• NeuroOne Medical Technologies Files Q3 2024 10-Q — 10-Q · Feb 12, 2025 Risk: medium
  NeuroOne Medical Technologies Corporation filed its 10-Q for the quarterly period ended December 31, 2024. The company, incorporated in Delaware with its princi
• NeuroOne Medical Technologies Files Definitive Additional Materials — DEFA14A · Feb 7, 2025 Risk: low
  NeuroOne Medical Technologies Corporation filed a Definitive Additional Materials filing (DEFA14A) on February 7, 2025. This filing relates to their proxy state
• NeuroOne Medical Technologies Files Additional Proxy Materials — DEFA14A · Feb 5, 2025 Risk: low
  NeuroOne Medical Technologies Corp. filed a Definitive Additional Materials document on February 5, 2025, related to its proxy statement. The company, previousl
• NeuroOne Medical Technologies Files 8-K — 8-K · Feb 4, 2025 Risk: low
  NeuroOne Medical Technologies Corporation filed an 8-K on February 4, 2025, reporting on events that occurred on February 3, 2025. The filing indicates the comp
• NeuroOne Medical Technologies Files Definitive Proxy Statement — DEF 14A · Jan 21, 2025 Risk: medium
  NeuroOne Medical Technologies Corp. filed its definitive proxy statement on January 21, 2025, for its annual meeting of stockholders. The filing, designated as
• NeuroOne Medical Technologies Files 8-K — 8-K · Jan 14, 2025 Risk: low
  NeuroOne Medical Technologies Corporation filed an 8-K on January 14, 2025, to report a Regulation FD Disclosure and Financial Statements and Exhibits. The fili
• NeuroOne Medical Technologies Files 8-K — 8-K · Jan 10, 2025 Risk: low
  NeuroOne Medical Technologies Corp. filed an 8-K on January 10, 2025, reporting on its results of operations and financial condition. The filing also includes i
• NeuroOne Medical Technologies Files 2024 10-K — 10-K · Dec 17, 2024 Risk: medium
  NeuroOne Medical Technologies Corporation filed its annual report for the fiscal year ended September 30, 2024. The company, incorporated in Delaware and headqu
• SC 13G/A Filing — SC 13G/A · Nov 25, 2024
• SC 13G/A Filing — SC 13G/A · Nov 14, 2024
• NeuroOne Medical Terminates Material Agreement — 8-K · Nov 8, 2024 Risk: medium
  NeuroOne Medical Technologies Corporation announced on November 7, 2024, the termination of a material definitive agreement. The company, incorporated in Delawa
• NeuroOne Medical Technologies Enters Material Agreement — 8-K · Oct 31, 2024 Risk: medium
  NeuroOne Medical Technologies Corporation announced on October 25, 2024, that it has entered into a material definitive agreement. The company also reported oth
• NeuroOne Medical Technologies Elects New Directors — 8-K · Sep 13, 2024 Risk: low
  NeuroOne Medical Technologies Corporation announced on September 9, 2024, a change in its board of directors. Specifically, the company elected two new director
• NeuroOne Medical Technologies Files Q2 2024 10-Q — 10-Q · Aug 14, 2024 Risk: low
  NeuroOne Medical Technologies Corporation filed its 10-Q for the quarterly period ended June 30, 2024. The company, incorporated in Delaware, operates in the su
• NeuroOne Medical Technologies Corp. Files 8-K — 8-K · Aug 7, 2024 Risk: medium
  NeuroOne Medical Technologies Corporation entered into a material definitive agreement on August 1, 2024, which created a direct financial obligation. The compa
• NeuroOne Medical Technologies Faces Delisting Notice — 8-K · Jul 12, 2024 Risk: high
  NeuroOne Medical Technologies Corporation filed an 8-K on July 11, 2024, to report a notice of delisting or failure to satisfy a continued listing rule. The com
• NeuroOne Medical Technologies Amends Corporate Documents — 8-K · Jun 21, 2024 Risk: low
  On June 20, 2024, NeuroOne Medical Technologies Corporation filed an 8-K report detailing amendments to its Articles of Incorporation. These changes, effective
• NeuroOne Medical Technologies Corp Files 10-Q for Period Ended March 31, 2024 — 10-Q · May 14, 2024 Risk:
  NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC) filed a Quarterly Report (10-Q) with the SEC on May 14, 2024. NeuroOne Medical Technologies Corporation filed a 10-Q r
• NeuroOne Medical Technologies Files 8-K — 8-K · Mar 26, 2024 Risk: low
  NeuroOne Medical Technologies Corporation filed an 8-K on March 26, 2024, reporting other events and financial statements. The company, incorporated in Delaware
• NeuroOne Medical Technologies Files 8-K — 8-K · Mar 15, 2024 Risk: low
  NeuroOne Medical Technologies Corp. filed an 8-K on March 14, 2024, reporting on matters submitted to a vote of security holders, Regulation FD disclosures, and
• SC 13G Filing — SC 13G · Feb 14, 2024
• NeuroOne Medical Technologies Corp. Files 10-Q for Period Ended December 31, 2023 — 10-Q · Feb 13, 2024 Risk: low
  NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC) filed a Quarterly Report (10-Q) with the SEC on February 13, 2024. NeuroOne Medical Technologies Corporation filed a 1
• NeuroOne Medical Technologies Corp. Announces 2024 Annual Meeting of Stockholders — DEF 14A · Jan 29, 2024 Risk: low
  NEUROONE MEDICAL TECHNOLOGIES Corp (NMTC) filed a Proxy Statement (DEF 14A) with the SEC on January 29, 2024. NeuroOne Medical Technologies Corp. will hold its
• Laurence Lytton Takes 1.3M Share Stake in NeuroOne Medical (NMTC) — SC 13G · Jan 11, 2024
  Laurence W. Lytton, an individual investor, has reported beneficial ownership of 1,304,102 shares of NeuroOne Medical Technologies Corp. (NMTC) common stock as

Risk Profile

Risk Assessment: Of NMTC's 31 recent filings, 3 were flagged as high-risk, 8 as medium-risk, and 20 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.

Key Executives

• Jeffrey S. Mathiesen
• BUCKMAN PAUL
• 0001215243
• Chief Executive Officer
• Dr. David L. Bear
• Mr. David J. Smith

Industry Context

NeuroOne Medical Technologies operates in the highly competitive and regulated medical device sector, specifically focusing on neurological disorders and pain management. The industry is characterized by significant R&D investment, long product development cycles, and stringent FDA approval processes. Key trends include the development of minimally invasive technologies, integrated diagnostic and therapeutic solutions, and the increasing demand for treatments for conditions like epilepsy, Parkinson's, and chronic pain.

Top Tags

8-K (6) · 10-Q (5) · corporate-governance (5) · medical-devices (5) · regulatory-filing (4) · financial-reporting (3) · material-agreement (3) · SEC Filing (3) · insider-filing (2) · ownership-change (2)

Key Numbers

• Form Type: 4 — Statement of changes in beneficial ownership of securities
• Market Value of Non-Affiliate Shares: $25.5M — As of March 31, 2025, indicating a relatively small market capitalization.
• Outstanding Shares: 50.4M — As of December 12, 2025, reflecting the company's share count.
• FDA 510(k) Clearances: 4 — Number of devices cleared by the FDA, including Evo Cortical, Evo sEEG, OneRF Brain Ablation, and OneRF TN Ablation Systems.
• Epilepsy Patients in US: 3M — Estimated annual patients suffering from epilepsy in the United States, highlighting a large target market.
• Epilepsy Surgeries Annually: 5,000 — Estimated number of epilepsy surgeries performed each year in the United States, indicating an underpenetrated market.
• Average Diagnostic Technology Cost: $10,000 — Per procedure, which NMTC aims to reduce with its 'all-in-one' solutions.
• Average Ablation Device Cost: $15,000 — Per procedure, another cost NMTC's integrated solutions could impact.
• Trigeminal Neuralgia Patients in US: 150,000 — Number of people living with TN in the US, representing another significant market.
• Global SCS Market Value: $2.5B-$3B — Estimated value of the global Spinal Cord Stimulation market, a target for NMTC's products in development.
• Potential Drug Delivery Market: $1B+ — Estimated full market commercial opportunity for NMTC's drug delivery application.
• Product revenue for nine months ended June 30, 2025: $6,356,767 — Increased 99.8% from $3,180,719 in prior year
• License revenue for nine months ended June 30, 2025: $3,000,000 — New revenue stream compared to $0 in prior year
• Net loss for nine months ended June 30, 2025: $1,986,153 — Significantly reduced from $8,967,515 in prior year
• Cash and cash equivalents as of June 30, 2025: $8,039,683 — Increased from $1,460,042 at September 30, 2024

Related Companies

ZBH · MDT · BSX · NEUR

Frequently Asked Questions